spironolactone has been researched along with Hyperphosphatemia in 3 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Hyperphosphatemia: A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vascular calcification is frequently found already in early stages of chronic kidney disease (CKD) patients and is associated with high cardiovascular risk." | 6.50 | Impact of aldosterone on osteoinductive signaling and vascular calcification. ( Alesutan, I; Lang, F; Ritz, E; Voelkl, J, 2014) |
| "Vascular calcification is frequently found already in early stages of chronic kidney disease (CKD) patients and is associated with high cardiovascular risk." | 2.50 | Impact of aldosterone on osteoinductive signaling and vascular calcification. ( Alesutan, I; Lang, F; Ritz, E; Voelkl, J, 2014) |
| "Spironolactone (SPL) has been proven to improve cardiovascular outcomes in clinical trials and its protective effect on VC has been reported recently; however, the underlying mechanisms are not completely understood and require further investigation." | 1.51 | Spironolactone dose‑dependently alleviates the calcification of aortic rings cultured in hyperphosphatemic medium with or without hyperglycemia by suppressing phenotypic transition of VSMCs through downregulation of Pit‑1. ( Chen, W; Luo, D; Peng, D; Quan, Z; Wang, P, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, P | 1 |
| Quan, Z | 1 |
| Luo, D | 1 |
| Chen, W | 1 |
| Peng, D | 1 |
| Lang, F | 1 |
| Ritz, E | 1 |
| Alesutan, I | 1 |
| Voelkl, J | 1 |
| Tatsumoto, N | 1 |
| Yamada, S | 1 |
| Tokumoto, M | 1 |
| Eriguchi, M | 1 |
| Noguchi, H | 1 |
| Torisu, K | 1 |
| Tsuruya, K | 1 |
| Kitazono, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients[NCT03314493] | Phase 3 | 33 participants (Actual) | Interventional | 2014-11-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for spironolactone and Hyperphosphatemia
| Article | Year |
|---|---|
Impact of aldosterone on osteoinductive signaling and vascular calcification.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Humans; Hyperphosphatemia; Mice; Mineralocorticoid Re | 2014 |
2 other studies available for spironolactone and Hyperphosphatemia
| Article | Year |
|---|---|
Spironolactone dose‑dependently alleviates the calcification of aortic rings cultured in hyperphosphatemic medium with or without hyperglycemia by suppressing phenotypic transition of VSMCs through downregulation of Pit‑1.
Topics: Animals; Dose-Response Relationship, Drug; Gene Expression Regulation; Hyperphosphatemia; Immunophen | 2019 |
Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.
Topics: Adenine; Animals; Aorta, Abdominal; Aortic Diseases; Apoptosis; Biomarkers; Disease Models, Animal; | 2015 |